Advertisement

Molecular Diagnosis & Therapy

, Volume 23, Issue 6, pp 751–760 | Cite as

HLA Correlations with Clinical Phenotypes and Risk of Metabolic Comorbidities in Singapore Chinese Psoriasis Patients

  • Meixin Shen
  • Soon Wei Daniel Lim
  • Eugene S. Tan
  • Hazel H. OonEmail author
  • Ee Chee RenEmail author
Original Research Article
  • 47 Downloads

Abstract

Introduction

Psoriasis is a systemic, chronic inflammatory disease that not only afflicts the skin but is also associated with cardiovascular disease and metabolic syndrome. The strongest susceptibility loci for the disease is within the human leukocyte antigen (HLA) complex, though specific HLA allelic associations vary between populations.

Objective

Our objective was to investigate HLA associations with clinical phenotypes of psoriasis and metabolic syndrome in Chinese psoriasis cases.

Methods

We conducted an observational case–control study in Singapore with a cohort of psoriasis cases consecutively recruited from an outpatient specialist dermatological center (n = 120) compared with 130 healthy controls.

Results

Significant HLA associations with psoriasis were observed with HLA-A*02:07, B*46:01, C*01:02, and C*06:02. The three-locus haplotype of A*02:07-C*01:02-B*46:01 was also significant (odds ratio [OR] 3.07; p = 9.47 × 10−5). We also observed an association between nail psoriasis and HLA-A*02:07 carriers (OR 4.50; p = 0.002), whereas C*06:02 carriers were less prone to have nail involvement (OR 0.16; p = 0.004). HLA-A*02:07 was also identified as a possible risk allele for hypertension (OR 2.90; p < 0.05), and C*01:02 was a possible risk allele for dyslipidemia (OR 3.36; p < 0.05), both known to be common comorbidities in patients with psoriasis.

Conclusion

Our results demonstrate the growing importance of discerning population-specific clinical phenotypes and their association with certain HLA alleles in psoriasis.

Notes

Acknowledgements

The authors are grateful for the support of research coordinators from the National Skin Centre: Jie Si Kwa, Yan Qin Mak, Umairah Adnan, Joan Fung and Veron Lu.

Compliance with Ethical Standards

Conflict of interest

MS, SWDL, EST, HHO, and ECR have no conflicts of interest that are directly relevant to the content of this article.

Funding

This study was funded by Singapore Immunology Network F00006 core fund.

Ethical approval and informed consent

This clinical study was approved by the IRB on “Genetic susceptibility in psoriasis with psoriatic arthritis and metabolic syndrome” (IRB number 2014/01132) and conducted according to the principles of the Declaration of Helsinki.

Supplementary material

40291_2019_423_MOESM1_ESM.pdf (119 kb)
Supplementary material 1 (PDF 118 kb)

References

  1. 1.
    Valdimarsson H, Bake BS, Jónsdótdr I, Fry L. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today. 1986;7:256–9.PubMedGoogle Scholar
  2. 2.
    Fry L. Psoriasis. Br J Dermatol. 1988;119:445–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.PubMedGoogle Scholar
  4. 4.
    Henseler T, Christophers E. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450–6.PubMedGoogle Scholar
  5. 5.
    Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.PubMedGoogle Scholar
  6. 6.
    Chen L, Tsai T-F. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178:854–62.PubMedGoogle Scholar
  7. 7.
    Brazzelli V, Quaglini M, Martinetti M, Nolli G, Salvaneschi L, Cuccia M, et al. A peculiar sequence motif in the alpha-1-domain of the HLA-C molecule in psoriasis. Dermatology. 2000;200:99–103.PubMedGoogle Scholar
  8. 8.
    Stuart PE, Nair RP, Hiremagalore R, Kullavanijaya P, Kullavanijaya P, Tejasvi T, et al. Comparison of MHC class I risk haplotypes in Thai and Caucasian psoriatics shows locus heterogeneity at PSORS1. Tissue Antigens. 2010;76:387–97.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Gudjonsson JE, Karason A, Antonsdottir A, Runarsdottir EH, Hauksson VB, Upmanyu R, et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol. 2003;148:233–5.PubMedGoogle Scholar
  10. 10.
    Gudjonsson JE, Karason A, Hjaltey Runarsdottir E, Antonsdottir AA, Hauksson VB, Jónsson HH, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients—an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol. 2006;126:740–5.PubMedGoogle Scholar
  11. 11.
    Tiilikainen A, Lassus A, Karvonen J, Vartiainen P, Julin M. Psoriasis and HLA-Cw6. Br J Dermatol. 1980;102:179–84.PubMedGoogle Scholar
  12. 12.
    Guðjónsson JE, Valdimarsson H, Kárason A, Antonsdóttir AA, Hjaltey Rúnarsdóttir E, Gulcher JR, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol. 2002;118:362–5.Google Scholar
  13. 13.
    Ozawa A, Miyahara M, Sugai J, Iizuka M, Kawakubo Y, Matsuo I, et al. HLA Class I and II alleles and susceptibility to generalized pustular psoriasis: significant associations with HLA-Cw1 and HLA-DQB1*0303. J Dermatol. 1998;25:573–81.PubMedGoogle Scholar
  14. 14.
    Choonhakarn C, Romphruk A, Puapairoj C, Jirarattanapochai K, Romphruk A, Leelayuwat C. Haplotype associations of the major histocompatibility complex with psoriasis in Northeastern Thais. Int J Dermatol. 2002;41:330–334.PubMedGoogle Scholar
  15. 15.
    Chiu HY, Huang P-Y, Jee S-H, Hu C-Y, Chou C-T, Chang Y-T, et al. HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis. Br J Dermatol. 2012;166:288–297.PubMedGoogle Scholar
  16. 16.
    Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS One. 2017;12:e0181039.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Singh S, Young P, Armstrong AW. Relationship between psoriasis and metabolic syndrome: a systematic review. G Ital di Dermatologia e Venereol. 2016;151:663–77.Google Scholar
  18. 18.
    Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133:2340–6.PubMedGoogle Scholar
  19. 19.
    Ahdout J, Kotlerman J, Elashoff D, Kim J, Chiu MW. Modifiable lifestyle factors associated with metabolic syndrome in patients with psoriasis. Clin Exp Dermatol. 2012;37:477–83.PubMedGoogle Scholar
  20. 20.
    Chen Q, Shen M, Heng YK, Theng TSC, Tey HL, Ren EC, et al. Actinic prurigo in Singaporean Chinese: a positive association with HLA-DRB1*03:01. Photochem Photobiol. 2016;92:355–9.PubMedGoogle Scholar
  21. 21.
    Dormoy A, Froelich N, Leisenbach R, Weschler B, Cazenave J-P, Tongio M-M. Mono-allelic amplification of exons 2-4 using allele group-specific primers for sequence-based typing (SBT) of the HLA-A, -B and -C genes: preparation and validation of ready-to-use pre-SBT mini-kits. Tissue Antigens. 2003;62:201–16.PubMedGoogle Scholar
  22. 22.
    Sayer D, Whidborne R, Brestovac B, Trimboli F, Witt C, Christiansen F. HLA-DRB1 DNA sequencing based typing: an approach suitable for high throughput typing including unrelated bone marrow registry donors. Tissue Antigens. 2001;57:46–54.PubMedGoogle Scholar
  23. 23.
    Jee S-H, Tsai T-F, Tsai W-L, Liaw S-H, Chang C-H, Hu C-Y. HLA-DRB1*0701 and DRB1*1401 are associated with genetic susceptibility to psoriasis vulgaris in a Taiwanese population. Br J Dermatol. 1998;139:978–83.PubMedGoogle Scholar
  24. 24.
    Zhang X, Wei S, Yang S, Wang Z, Zhang A, He P, et al. HLA-DQA1 and DQB1 alleles are associated with genetic susceptibility to psoriasis vulgaris in Chinese Han. Int J Dermatol. England. 2004;43:181–7.Google Scholar
  25. 25.
    Hirata J, Hirota T, Ozeki T, Kanai M, Sudo T, Tanaka T, et al. Variants at HLA-A, HLA-C, and HLA-DQB1 Confer risk of psoriasis vulgaris in Japanese. J Invest Dermatol. 2018;138:542–8.PubMedGoogle Scholar
  26. 26.
    Zhang X-J, Zhang A-P, Yang S, Gao M, Wei S-C, He P-P, et al. Association of HLA class I alleles with psoriasis vulgaris in southeastern Chinese Hans. J Dermatol Sci. 2003;33:1–6.PubMedGoogle Scholar
  27. 27.
    Lebwohl M. Psoriasis. Lancet. 2003;361:1197–204.PubMedGoogle Scholar
  28. 28.
    Yin X, Wineinger NE, Cheng H, Cui Y, Zhou F, Zuo X, et al. Common variants explain a large fraction of the variability in the liability to psoriasis in a Han Chinese population. BMC Genomics. 2014;15:87.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Fan X, Yang S, Sun L, Liang Y, Gao M, Zhang K, et al. Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol. 2007;87:335–40.PubMedGoogle Scholar
  30. 30.
    Guarene M, Pasi A, Bolcato V, Cananzi R, Piccolo A, Sbarsi I, et al. The presence of HLA-A Bw4-80I KIR ligands could predict “Difficult-to-Treat” psoriasis and poor response to etanercept. Mol Diagn Ther. 2018;22:471–4.PubMedGoogle Scholar
  31. 31.
    Foley BA, Santis DD, Van Beelen E, Lathbury LJ, Christiansen FT, Witt CS. The reactivity of Bw4 + HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood. 2008;112:435–43.PubMedGoogle Scholar
  32. 32.
    Shen M, Linn Y-C, Ren EC. KIR-HLA profiling shows presence of higher frequencies of strong inhibitory KIR-ligands among prognostically poor risk AML patients. Immunogenetics. 2016;68:133–44.PubMedGoogle Scholar
  33. 33.
    Hildebrand WH, Domena JD, Shen SY, Lau M, Terasaki PI, Bunce M, et al. HLA-B15: a widespread and diverse family of HLA-B alleles. Tissue Antigens. 1994;43:209–18.PubMedGoogle Scholar
  34. 34.
    Hilton HG, McMurtrey CP, Han AS, Djaoud Z, Guethlein LA, Blokhuis JH, et al. The intergenic recombinant HLA-B∗46:01 has a distinctive peptidome that includes KIR2DL3 ligands. Cell Rep. 2017;19:1394–405.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Abi-Rached L, Moesta AK, Rajalingam R, Guethlein LA, Parham P. Human-specific evolution and adaptation led to major qualitative differences in the variable receptors of human and chimpanzee natural killer cells. Malik HS, editor. PLoS Genet. 2010;6:e1001192.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Gonzalez-Galarza FF, Takeshita LYCC, Santos EJMM, Kempson F, Maia MHT, da Silva ALS, et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 2015;43:D784–8.PubMedGoogle Scholar
  37. 37.
    Okada Y, Han B, Tsoi LC, Stuart PE, Ellinghaus E, Tejasvi T, et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet. 2014;95:162–72.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Yin X, Low HQ, Wang L, Li Y, Ellinghaus E, Han J, et al. Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nat Commun. 2015;6:6916.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Kim T-G, Han H, Lee HJ, Youn J Il, Kim TY. The association of psoriasis with human leukocyte antigens in Korean population and the influence of age of onset and sex. J Invest Dermatol. 2000;114:309–13.PubMedGoogle Scholar
  40. 40.
    Lam TH, Shen M, Chia J-M, Chan SH, Ren EC. Population-specific recombination sites within the human MHC region. Heredity (Edinb). 2013;111:131–8.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Usui T, Tailor A, Faulkner L, Meng X, Farrell J, Daly AK, et al. HLA-A*33:03-restricted activation of ticlopidine-specific T-cells from human donors. Chem Res Toxicol. 2018;31:1022–4.PubMedGoogle Scholar
  42. 42.
    Chang L-Y, Chang I-S, Chen W-J, Huang Y-C, Chen G-W, Shih S-R, et al. HLA-A33 is associated with susceptibility to enterovirus 71 infection. Pediatrics. 2008;122:1271–6.PubMedGoogle Scholar
  43. 43.
    Hildesheim A, Apple RJ, Chen C-J, Wang SS, Cheng Y-J, Klitz W, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 2002;94:1780–9.PubMedGoogle Scholar
  44. 44.
    Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321–8.PubMedGoogle Scholar
  45. 45.
    Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157:68–73.PubMedGoogle Scholar
  46. 46.
    Armstrong EJ, Krueger JG. Lipoprotein metabolism and inflammation in patients with psoriasis. Am J Cardiol. 2016;118:603–9.PubMedGoogle Scholar
  47. 47.
    Asha K, Singal A, Sharma S, Arora V, Aggarwal A. Dyslipidaemia & oxidative stress in patients of psoriasis: emerging cardiovascular risk factors. Indian J Med Res. 2017;146:708.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189–97.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet. 2009;41:47–55.PubMedGoogle Scholar
  50. 50.
    Horibe H, Ueyama C, Fujimaki T, Oguri M, Kato K, Ichihara S, et al. Association of a polymorphism of BTN2A1 with dyslipidemia in community-dwelling individuals. Mol Med Rep. 2014;9:808–12.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Singapore Immunology Network (SIgN), A*STARSingaporeSingapore
  2. 2.John A. Paulson School of Engineering and Applied SciencesHarvard UniversityCambridgeUSA
  3. 3.National Skin Centre (S) Pte LtdSingaporeSingapore
  4. 4.Department of Microbiology and ImmunologyNational University of SingaporeSingaporeSingapore

Personalised recommendations